Super Micro, Ferrari, Marriott, Airbnb, Novo Nordisk, and More Stocks to Watch This Week
New Study Reveals Another Benefit in Using Novo Nordisk's Wegovy in Obesity
"Weight-loss miracle drug" has new therapeutic effects! novo-nordisk a/s (NVO.US) semaglutide MASH Phase 3 clinical trial meets primary endpoint.
Novo Nordisk announced on Friday that a key Phase 3 trial testing its obesity therapy semaglutide in patients with metabolic dysfunction associated with non-alcoholic steatohepatitis (NASH) has met its primary endpoint.
Top Gap Ups and Downs on Friday: AMZN, ABT, TEAM and More
Hoping for a Weight-loss Pill? It Could Be Closer to Reality Next Week.
Correction to Novo Nordisk Article
